TY - JOUR T1 - Single-cell RNA sequencing reveals <em>in vivo</em> signatures of SARS-CoV-2-reactive T cells through ‘reverse phenotyping’ JF - medRxiv DO - 10.1101/2020.12.07.20245274 SP - 2020.12.07.20245274 AU - David S. Fischer AU - Meshal Ansari AU - Karolin I. Wagner AU - Sebastian Jarosch AU - Yiqi Huang AU - Christoph H. Mayr AU - Maximilian Strunz AU - Niklas J. Lang AU - Elvira D’Ippolito AU - Monika Hammel AU - Laura Mateyka AU - Simone Weber AU - Lisa S. Wolff AU - Klaus Witter AU - Isis E. Fernandez AU - Gabriela Leuschner AU - Kathrin Milger AU - Marion Frankenberger AU - Lorenz Nowak AU - Katharina Heinig-Menhard AU - Ina Koch AU - Mircea G. Stoleriu AU - Anne Hilgendorff AU - Jürgen Behr AU - Andreas Pichlmair AU - Benjamin Schubert AU - Fabian J. Theis AU - Dirk H. Busch AU - Herbert B. Schiller AU - Kilian Schober Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/08/2020.12.07.20245274.abstract N2 - The in vivo phenotypic profile of T cells reactive to severe acute respiratory syndrome (SARS)-CoV-2 antigens remains poorly understood. Conventional methods to detect antigen-reactive T cells require in vitro antigenic re-stimulation or highly individualized peptide-human leukocyte antigen (pHLA) multimers. Here, we used single-cell RNA sequencing to identify and profile SARS-CoV-2-reactive T cells from Coronavirus Disease 2019 (COVID-19) patients. To do so, we induced transcriptional shifts by antigenic stimulation in vitro and took advantage of natural T cell receptor (TCR) sequences of clonally expanded T cells as barcodes for ‘reverse phenotyping’. This allowed identification of SARS-CoV-2-reactive TCRs and revealed phenotypic effects introduced by antigen-specific stimulation. We characterized transcriptional signatures of currently and previously activated SARS-CoV-2-reactive T cells, and showed correspondence with phenotypes of T cells from the respiratory tract of patients with severe disease in the presence or absence of virus in independent cohorts. Reverse phenotyping is a powerful tool to provide an integrated insight into cellular states of SARS-CoV-2-reactive T cells across tissues and activation states.Competing Interest StatementD.H.B. is co-founder of STAGE Cell Therapeutics GmbH (now Juno Therapeutics/BMS) and T Cell Factory B.V. (now Kite/Gilead). D.H.B. has a consulting contract with and receives sponsored research support from Juno Therapeutics/BMS. F.J.T. reports receiving consulting fees from Roche Diagnostics GmbH and Cellarity Inc., and ownership interest in Cellarity, Inc. and Dermagnostix. The other authors have no financial conflicts of interest.Funding StatementK.S., D.H.B. and K.I.W. acknowledge support by the German National Network of University Medicine of the Federal Ministry of Education and Research (BMBF; NaFoUniMedCovid19, 01KX2021; COVIM), as well as the German Center for Infection Research (DZIF) and the German Research Foundation (DFG; SFB 1321/TP17; SFB 1054/B09 and SFB 1371/TP04). H.B.S. and M.A. acknowledge support by the German Center for Lung Research (DZL), the Helmholtz Association, the BMBF project Single Cell Genomics Network Germany, the European Union's Horizon 2020 research and innovation program (grant agreement 874656). F.J.T. acknowledges support by the BMBF (01IS18036B and 01IS18053A) and the Chan Zuckerberg Initiative (2019-207271 and 2019-207271) and by the Helmholtz Association's Initiative and Networking Fund through Helmholtz AI (ZT-I-PF-5-01). D.S.F. acknowledges support from a German Research Foundation (DFG) fellowship through the Graduate School of Quantitative Biosciences Munich (QBM) [GSC 1006] and by the Joachim Herz Stiftung.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from the donors or their caregivers, usage of the blood samples was approved according to national law by the local Institutional Review Board (Ethikkommission der Medizinischen Fakultaet der Ludwigs-Maximilian-Universitet Muenchen; vote IDs 19-629, 19-630 and 20-259) and/or samples were used according to legal provisions defined by the German Infection Protection Act (IfSG).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this article and its supplementary information files. Additional raw data are available from the corresponding authors upon reasonable request. ER -